Verastem (VSTM) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Verastem Reports Third Quarter 2016 Financial Results
November 7, 2016 4:05 PM ESTCompany Adds Late-Stage, Complementary Oncology Product Candidate Duvelisib to Pipeline
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the third quarter ended September 30, 2016, and also provided an overview of certain corporate developments.
Last week, we announced the inlicensing of the late-stage oncology product candidate duvelisib from Infinity Pharmaceuticals. This transaction brings a complementary development program on attractive financial terms, said Robert Forrester, President and Chief Executive Officer of Verastem. Duvelisib has a proven mechanism of action and has... More
Verastem Announces Presentations at ASH Annual Meeting
November 3, 2016 9:14 AM EDTBOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the American Society of Hematology (ASH) 2016 Annual Meeting, being held December 3-6, 2016 in San Diego.
Data from DYNAMO®, a Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib in relapsed/refractory iNHL, will be presented in an oral session. Updated data from CONTEMPO, a Phase 1b/2 study evaluating duvelisib in combination with... More
